Coronavirus | India has key vaccine role: Anthony Fauci

Trump’s adviser says its manufacturing capabilities going to be very important.

July 30, 2020 12:29 pm | Updated 11:41 pm IST - NEW DELHI:

Dr Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases in Washington. File photo

Dr Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases in Washington. File photo

Anthony Fauci , top infectious disease specialist and senior adviser to U.S. President Donald Trump on COVID-19 , on Thursday said that India would play a critical role in supplying the world with a COVID-19 vaccine. 

At a web conference organised by the Indian Council for Medical Research, he, however, underlined that though the threat posed by COVID-19 was grave, it was not essential now to conduct human challenge trials to expedite vaccine development.

Also read | Serum Institute may manufacture 2-3 million Oxford vaccine doses in July

Dr. Fauci, who is the head of the U.S. National Institute of Allergy and Infectious Disease, said that two potential vaccines by Moderna and Pfizer were in advanced stages of human trials. 

“India’s manufacturing capabilities is going to be very important. We have made it clear that all tests on vaccines will have to meet regulatory standards and include all ethical review and strong data monitoring and safety boards,” he said at the conference attended by top officials from the ICMR, the Departments of Biotechnology and the Health Ministry.

Human trials

Human challenge trials involve intentionally infecting healthy vaccinated volunteers with small amounts of the virus. That way researchers can come to know relatively quickly if a test-vaccine works. While such trials have been conducted for malaria and dengue, researchers are divided on their ethics. Since COVID-19 is caused by a novel virus and does not have a standard treatment protocol, it is unethical to expose healthy volunteers to that level of risk.

Watch | Oxford's COVID-19 vaccine shows positive results

“We recently convened an expert consultation on the issue and the conclusion was that such studies are not necessary at this time. The continuing high incidence of the disease is concerning but it makes randomised control trials quite feasible. We don’t have effective therapies to cure individuals infected. These factors have led us to conclude that human challenges are not essential nor ethically justified presently”, he said. The conference also saw discussions on a way to ensure that a vaccine, if and when available, is equitably distributed. 

Equitable access

Rajesh Bhushan, who will take over as Health Secretary soon, said discussions were under way in the government on the most appropriate way to ensure equitable access to vaccines. “Healthcare workers would be a priority. But there are several other stakeholders, the elderly, those with comorbidities and those extremely marginalised and because of socio-economic conditions are likely to be at particular risk of being severely ill by the infection.”

The conference also saw speakers from several leading research institutions in Europe as well representatives from collectives such as the Coalition for Epidemic Preparedness that are involved in myriad vaccine development projects.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.